Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,091JPY
21 Sep 2017
Change (% chg)

¥-15 (-0.25%)
Prev Close
¥6,106
Open
¥6,158
Day's High
¥6,189
Day's Low
¥6,090
Volume
3,393,300
Avg. Vol
1,893,678
52-wk High
¥6,199
52-wk Low
¥4,321

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.70
Market Cap(Mil.): ¥4,828,727.00
Shares Outstanding(Mil.): 790.82
Dividend: 90.00
Yield (%): 2.95

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.33
EPS (TTM): -- -- --
ROI: -- 15.11 14.66
ROE: -- 16.37 13.99

Fujifilm says aims to spend $4.5 billion on M&A over three years

TOKYO Fujifilm Holdings Corp said it aimed to spend 500 billion yen ($4.54 billion) in strategic acquisitions over three years as it seeks growth outside its traditional photographic film business, which has been shrinking.

Aug 30 2017

Fujifilm says aims to spend $4.5 bln on M&A over 3 years

TOKYO, Aug 30 Fujifilm Holdings Corp said it aimed to spend 500 billion yen ($4.54 billion) in strategic acquisitions over three years as it seeks growth outside its traditional photographic film business, which has been shrinking.

Aug 30 2017

AstraZeneca strikes $400 million Parkinson's drug deal with Takeda

LONDON AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson's disease.

Aug 29 2017

AstraZeneca strikes $400 mln Parkinson's drug deal with Takeda

LONDON, Aug 29 AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson's disease.

Aug 29 2017

Samsung Bioepis teams up with Takeda to develop original biotech drugs

SEOUL Samsung Bioepis Co Ltd said on Monday it will fund and develop multiple original drugs in partnership with Japan's Takeda Pharmaceutical Co Ltd, expanding its business scope beyond copies of existing biologic drugs.

Aug 20 2017

Samsung Bioepis teams up with Takeda to develop original biotech drugs

* Bioepis' Enbrel copy generated over $250 mln in sales since 2016

Aug 20 2017

BRIEF-Takeda Pharmaceutical Co reports 10.9 pct stake in Molecular Templates - SEC Filing‍​

* Takeda Pharmaceutical Company reports 10.9 percent stake in Molecular Templates Inc as of August 1, 2017 - SEC Filing‍​ Source text: (http://bit.ly/2vTAtQL) Further company coverage:

Aug 10 2017

BRIEF-Takeda and Shattuck Labs announce research collaboration

* Takeda and Shattuck Labs announce research collaboration to explore agonist redirected checkpoint fusion proteins in immuno-oncology

Aug 10 2017

BRIEF-Takeda and Cardurion Pharmaceuticals launch cardiovascular development partnership

* Takeda and Cardurion Pharmaceuticals launch cardiovascular development partnership

Aug 02 2017

UPDATE 1-Japanese drugmaker Takeda posts stronger profit as U.S. sales jump

* Astellas Q1 operating profit halves from year ago (Adds wider industry context, Astellas results)

Jul 28 2017

Earnings vs. Estimates